Supplementary Tables S1-S5 from Inhibition of mTORC1/2 Overcomes Resistance to MAPK Pathway Inhibitors Mediated by PGC1α and Oxidative Phosphorylation in Melanoma

Supplementary Tables S1-S5. Table S1. Patients in the MIA/WH cohort treated with BRAF and/or MEK inhibitors. Table S2. Patients in the MGH patient cohort were treated with the BRAF inhibitor vemurafenib or a combination of BRAF and MEK inhibitors (dabrafenib+trametinib). Table S3. The following melanoma cell lines with known BRAF and NRAS mutation status were seeded in 96 well plates overnight and treated with increasing concentrations (dose range 9nM-6.5mM) of selumetinib (SEL), AZD8055 or their combination. Table S4. Mutations detected in the selumetinib-resistant A375 and WM35 cell line clones compared to their parental cell lines. Table S5. Hugo gene symbols, chromosomal location and gene names of the 202 genes represented in the T200 exon sequencing panel.